Corvus Pharmaceuticals Reports Positive Q3 Earnings Call

Corvus Pharmaceuticals Inc. recently held its earnings call, revealing a generally positive outlook with several significant developments. The company reported a notable reduction in net loss, a robust cash position, and successful clinical trial progress for soquelitinib. Despite facing challenges such as increased R&D expenses and delays in trial result reporting, the positive aspects, particularly related to clinical advancements and financial improvements, appear to outweigh the negatives. Significant Reduction in Net Loss Corvus Pharmaceuticals reported a substantial decrease in its net loss for the third quarter of 2025. The net loss was $10.2 million, a significant improvement from the $40.2 million loss recorded in the same quarter of the previous year. This reduction highlights the company’s efforts to streamline operations and improve financial performance. Strong Cash Position The company maintained a strong cash position, with cash, cash equivalents, and marketable securities totaling $65.7 million as of September 30, 2025. This is an increase from $52 million at the end of 2024, indicating a solid financial foundation to support ongoing and future operations. Successful Enrollment in Phase I Trial for Soquelitinib Corvus Pharmaceuticals successfully completed enrollment for the extension Cohort 4 of the Phase I trial for soquelitinib. The results from this trial are anticipated in January 2026, marking a crucial step in the drug’s development process. Upcoming Phase II Trial for Atopic Dermatitis The company is on track to initiate a Phase II trial for atopic dermatitis using soquelitinib in early Q1 2026. This trial will involve approximately 200 patients globally, showcasing Corvus’s commitment to advancing its clinical pipeline. Positive Efficacy Data for Soquelitinib Cohort 3 of the Phase I trial for soquelitinib demonstrated promising results, with a mean percent reduction of the EASI score by 64.8%. This positive efficacy data underscores the potential of soquelitinib as a treatment option. Presentation at ASH for T Cell Lymphoma Corvus Pharmaceuticals is set to present the final results from its Phase I/Ib clinical trial of soquelitinib for relapsed/refractory T cell lymphomas at the upcoming ASH meeting in December. This presentation will provide further insights into the drug’s efficacy and safety profile. Increased Research and Development Expenses The company’s R&D expenses increased to $8.5 million in Q3 2025, up from $5.2 million in the same period of 2024. This rise is primarily attributed to higher clinical trial and manufacturing costs associated with soquelitinib development. Noncash Loss Related to Angel Pharmaceuticals Corvus reported a noncash loss of $300,000 related to Angel Pharmaceuticals in Q3 2025, which is a decrease from the $700,000 loss reported in the same period in 2024. This reduction reflects improved financial management and strategic adjustments. Delayed Reporting of Phase I Trial Results The results from the extension Cohort 4 of the Phase I trial for soquelitinib will be delayed until January 2026. This delay may impact the timeline for gaining further insights into the drug’s development. Forward-Looking Guidance During the earnings call, CFO Leiv Lea highlighted key financial metrics, including a significant reduction in net loss and increased R&D expenses due to soquelitinib development. The company expects its current funds to support operations into Q4 2026. CEO Richard Miller emphasized the completion of enrollment for the Phase I trial and the upcoming Phase II trial for atopic dermatitis, scheduled for early Q1 2026. In summary, Corvus Pharmaceuticals’ earnings call reflected a positive sentiment, driven by financial improvements and clinical progress. Despite some challenges, the company’s strategic focus on advancing its clinical pipeline and maintaining a strong financial position suggests a promising outlook for the future.